Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Sep 2025: Owkin planned to cut about 50 of 325 jobs via a voluntary departure scheme as it refocused on AI; in Mar 2026 it spun out its diagnostics unit as Waiv with $33m of external financing.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator (e.g. CNIL) actions involving Owkin found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No recalls, safety notices or regulator actions involving Owkin found in HSH's search of the last 24 months. Its CE-marked AI pathology diagnostics moved to spin-out Waiv, which reported IVDR CE marking in Apr 2026.
Contract delivery, go-lives, terminations and disputes.
May 2026: Owkin and AstraZeneca expanded their AI collaboration with a multi-year research agreement for Owkin's K Pro platform. No customer disputes or terminations found in HSH's search of the last 24 months.